Mark Frohlich

Company: Indapta Therapeutics

Job title: Chief Executive Officer

Seminars:

Case Study: Key Considerations for Developing a Combination Product 9:00 am

Discussing the development of g-NK cell therapy with antibody combinations for NHL and AML Understanding how to navigate regulations and patient treatment procedures with multiple treatment regiments Highlighting positive clinical data reinforcing the rationale behind a combination approachRead more

day: Day 2 AM